Indivior lifted full-year revenue and EBITDA forecasts following 19% YoY Q1 growth and a $175 million share repurchase plan.
Indivior Pharmaceuticals raised its 2026 guidance to $1.215–$1.285 billion in net revenue and $620–$660 million in adjusted EBITDA after Q1 results. Revenue reached $317 million, up 19% YoY, while adjusted EBITDA surged 112% to $164 million.
The company’s SUBLOCADE franchise, with $232 million in revenue and 32% growth, drove performance. Despite pipeline setbacks, Indivior announced a $175 million accelerated share repurchase, adding to $125 million in Q1 buybacks.
Shares traded at $37.39 as of June 8, with trailing and forward P/E ratios of 19.30 and 12.27, respectively.